(391 days)
No
The description focuses on the mechanical and cryosurgical aspects of the device, with no mention of AI or ML in the device description, performance studies, or key metrics. The software testing mentioned is for general software conformance, not AI/ML specific validation.
Yes
The device is described as a "cryosurgical tool" intended for "ablation of Barrett's Esophagus with dysplasia," which indicates its use in treating a medical condition.
No
The device is described as a "cryosurgical tool" intended for "ablation of Barrett's Esophagus with dysplasia," which is a treatment procedure, not a diagnostic one.
No
The device description clearly outlines multiple hardware components: a catheter, a controller, a foot pedal, and a nitrous oxide cartridge. While the controller has a software interface, the system is fundamentally a hardware-based cryosurgical device.
Based on the provided information, the C2 CryoBalloon™ Ablation System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for cryosurgical ablation of tissue (Barrett's Esophagus with dysplasia) within the body, using an endoscopic approach. This is a therapeutic procedure performed directly on the patient.
- Device Description: The device components and mechanism of action involve delivering a cryogen to freeze tissue in situ. It does not involve testing samples of biological material outside the body to diagnose a condition.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue samples, etc.) or providing diagnostic information based on such analysis. The device is used for treatment, not diagnosis.
IVD devices are specifically designed to examine specimens derived from the human body to provide information for the diagnosis, monitoring, or treatment of a disease or condition. The C2 CryoBalloon™ Ablation System does not fit this definition.
N/A
Intended Use / Indications for Use
The C2 CryoBalloon™ Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett's Esophagus with dysplasia.
Product codes
GEH
Device Description
The C2 CryoBalloon Ablation System is a cryosurgical device, which consists of four (4) components: (i) a single-use, sterile balloon Catheter that is inserted through the working channel of an endoscope with a minimum inner diameter (ID) of 3.7 mm and a maximum working length of 100 cm; (ii) a hand-held reusable Controller with a liquid crystal display (LCD) touch screen interface; (iii) a reusable Foot Pedal that is plugged into mains, provides power for the Controller, and allows the user to operate system functions such as ablation targeting, nitrous oxide flow control, and balloon deflation; and (iv) single-use Nitrous Oxide Cartridge that provides users with cryogen for each treatment.
The C2 CryoBalloon Ablation System uses nitrous oxide as a cryogen to cause necrosis of targeted tissue in a controlled manner. The low operating pressure inflates the compliant balloon against the lumen ID. Nitrous oxide is directed at the targeted tissue and it evaporates on the inner surface of the balloon and freezes the tissue. The nitrous oxide is fully contained within the balloon and the resultant gas exhausts through the Catheter shaft and vents through the Controller.
There are four (4) Catheter configurations that distribute nitrous oxide focally (focal diffuser), over a quarter of the lumen circumference (90° diffuser), over half of the lumen circumference (180° diffuser), or over the full circumference of the lumen (360° diffuser). The user selects the Catheter with the desired diffuser type, removes it from the sterile packaging and inserts it through the working channel of an endoscope until the balloon portion exits the distal end of the endoscope.
The connector portion of the Catheter is inserted into the Controller and the radiofrequency identification (RFID) communication system in the Catheter connector and the Controller allows the Controller to perform functions specific to the Catheter. The LCD touch screen allows the user to set desired dosimetry, and communicates system status to the user.
The user tightens the Controller Cap against the Controller, which pierces the nitrous oxide Cartridge. Nitrous oxide is contained in the Controller until the user steps on the Foot Pedal to allow the Controller to release it into the Catheter. The user visualizes the targeting and ablation via the inflated balloon and the images provided by the endoscope. The balloon is held in contact with the treatment area during the ablation. Upon conclusion of the procedure the balloon is deflated and withdrawn into the endoscope.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Barrett's Esophagus
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Performance Data were provided for the C2 CryoBalloon Ablation System and its components in support of substantial equivalence determination. The following was performed on the subject C2 CryoBalloon Ablation System to evaluate physical reliability, safety, and effectiveness.
Testing Type: Bench Testing
Objectives: The nonclinical testing assessed functional performance of the system. The following describes the key aspects of the device that were tested:
• Simulated Use
○ Verify temperature uniformity and depth of penetration during cryogen application.
○ Verify system hold pressure is maintained with no leakage.
○ Verify controller reliability after 1-year of reuse.
• Dimensional Testing
○ Verify balloon and Catheter dimensions
○ Verify Catheter able to pass through 3.7mm or larger accessory channel.
• Mechanical Integrity
○ Verify rated burst pressure of balloon is sufficiently greater than nominal operating pressure
○ Tensile test all of the Catheter bonds
○ Verify balloon reliability after repeated inflations
Results: The subject C2 CryoBalloon Ablation System passed all functional testing and met all product specification requirements.
Testing Type: Software
Objectives: Perform testing to verify conformance to Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, Guidance for Industry and FDA Staff, May 11, 2005.
Results: The subject C2 CryoBalloon Ablation System met all software test requirements for software with a Major Level of Concern.
Testing Type: Electrical Safety
Objectives: Perform testing to verify conformance to the following standards:
• ES 60601-1:2005/(R)2012 And A1:2012
• IEC 60601-1-2:2007
• IEC 60601-1-6 Edition 3.1 2013 10
Results: The subject C2 CryoBalloon Ablation System met the electrical safety, electromagnetic compatibility, and coexistence test requirements and is fully compliant with all of the listed standards
Testing Type: Controller Reprocessing
Objectives: Perform testing to verify conformance to Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling Guidance for Industry and FDA Staff, March 17, 2015.
Perform microbial ingress testing to confirm contaminated (interior and exterior) Controller does not cross-contaminate the Catheter.
Results: The subject C2 CryoBalloon Controller's intermediate level cleaning and disinfection processes have been validated per FDA guidance.
The microbial ingress testing demonstrated that a contaminated Controller does not cross-contaminate the Catheter; therefore, Intermediate Level Cleaning and Disinfection are appropriate reprocessing processes for the subject device.
Testing Type: Biocompatibility
Objectives: Perform testing to verify conformance to the following standards:
• Use of International Standard ISO 10993-1, “Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process,” Guidance for Industry and FDA Staff, June 16, 2016
• ISO 10993-1:2009
• ISO 10993-5:2009
• ISO 10993-10:2010
Results: The subject C2 CryoBalloon Ablation System met the cytotoxicity, irritation, and sensitization requirements. The subject device materials are the same as the predicate devices.
Testing Type: Catheter Sterilization
Objectives: Perform testing to verify conformance to the following standards:
• ISO 11135:2014
Results: The subject C2 CryoBalloon Catheter met the sterilization and residuals requirements. The subject Catheter
Testing Type: Packaging/Shelf Life
Objectives: Perform testing to verify conformance to the following standards:
• ISO 11607-1:2006 (Catheter only)
• ASTM D4332-14
• ASTM D4169-14
• ASTM F2096-11 (Catheter only)
• ASTM F88-15 (Catheter only)
• ASTM F1929-15 (Catheter only)
Results: The subject C2 CryoBalloon Ablation System met the packaging test requirements.
Testing Type: Usability
Objectives: Perform testing to verify conformance to Applying Human Factors and Usability Engineering to Medical Devices, Guidance for Industry and FDA Staff, February 3, 2016.
Results: The subject C2 CryoBalloon Ablation System was found to be safe and effective for the intended user, uses, and use environment. Residual risks do not require device modification.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4350 Cryosurgical unit and accessories.
(a)
Identification —(1)Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold.(2)
Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold.(3)
Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing right, with flowing lines above them that resemble a bird's wing. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the image.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 23, 2018
C2 Therapeutics, Inc. Patrick Wu Director of Research and Development 303 Convention Way, Ste. 1 Redwood City, CA 94063
Re: K163684
Trade/Device Name: C2 Cryoballoon Ablation System Regulation Number: 21 CFR 878.4350 Regulation Name: Cryogenic unit and accessories Regulatory Class: Class II Product Code: GEH Dated: December 21, 2017 Received: December 22, 2017
Dear Patrick Wu:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours, Jennifer R. Stevenson -
S3
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K163684
Device Name
C2 CryoBalloon™ Ablation System
Indications for Use (Describe)
The C2 CryoBalloon™ Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett's Esophagus with dysplasia.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
3
510(k) Summary
This 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92.
I. SUBMITTER
C2 Therapeutics, Inc. 303 Convention Way, Suite 1 Redwood City, CA 94063
| Phone: | 408-368-6043 |
|---|---|
| Fax: | 650-556-1145 |
| Contact Person: | Patrick Wu |
| Director of Research and Development | |
| Date Prepared: | January 23, 2018 |
II. DEVICE
| Name of Device: | C2 CryoBalloon™ Ablation System (subject device) |
|---|---|
| Common Name: | Cryosurgical Unit, Cryogenic Surgical Device |
| Classification Name: | Cryosurgical Unit, Cryogenic Surgical Device |
| 21 CFR§878.4350(a)(2) | |
| Regulatory Class: | Class II |
| Product Code: | GEH |
III. PREDICATE DEVICE
| Predicate Devices: | Primary: |
|---|---|
| C2 Therapeutics, Inc. (K161202) | |
| C2 CryoBalloon™ Ablation System |
Secondary: C2 Therapeutics, Inc. (K152329) Coldplay CryoBalloon™ Focal Ablation System Coldplay CryoBalloon™ Full Ablation System Coldplay CryoBalloon™ Swipe Ablation System
4
IV. DEVICE DESCRIPTION
The C2 CryoBalloon Ablation System is a cryosurgical device, which consists of four (4) components: (i) a single-use, sterile balloon Catheter that is inserted through the working channel of an endoscope with a minimum inner diameter (ID) of 3.7 mm and a maximum working length of 100 cm; (ii) a hand-held reusable Controller with a liquid crystal display (LCD) touch screen interface; (iii) a reusable Foot Pedal that is plugged into mains, provides power for the Controller, and allows the user to operate system functions such as ablation targeting, nitrous oxide flow control, and balloon deflation; and (iv) single-use Nitrous Oxide Cartridge that provides users with cryogen for each treatment.
The C2 CryoBalloon Ablation System uses nitrous oxide as a cryogen to cause necrosis of targeted tissue in a controlled manner. The low operating pressure inflates the compliant balloon against the lumen ID. Nitrous oxide is directed at the targeted tissue and it evaporates on the inner surface of the balloon and freezes the tissue. The nitrous oxide is fully contained within the balloon and the resultant gas exhausts through the Catheter shaft and vents through the Controller.
There are four (4) Catheter configurations that distribute nitrous oxide focally (focal diffuser), over a quarter of the lumen circumference (90° diffuser), over half of the lumen circumference (180° diffuser), or over the full circumference of the lumen (360° diffuser). The user selects the Catheter with the desired diffuser type, removes it from the sterile packaging and inserts it through the working channel of an endoscope until the balloon portion exits the distal end of the endoscope.
The connector portion of the Catheter is inserted into the Controller and the radiofrequency identification (RFID) communication system in the Catheter connector and the Controller allows the Controller to perform functions specific to the Catheter. The LCD touch screen allows the user to set desired dosimetry, and communicates system status to the user.
The user tightens the Controller Cap against the Controller, which pierces the nitrous oxide Cartridge. Nitrous oxide is contained in the Controller until the user steps on the Foot Pedal to allow the Controller to release it into the Catheter. The user visualizes the targeting and ablation via the inflated balloon and the images provided by the endoscope. The balloon is held in contact with the treatment area during the ablation. Upon conclusion of the procedure the balloon is deflated and withdrawn into the endoscope.
V. INDICATIONS FOR USE
The C2 CryoBalloon™ Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett's Esophagus with dysplasia.
5
VL. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
Cryoablation is the fundamental technological principle for both the subject C2 CryoBalloon™ Ablation System and the predicate C2 CryoBalloon™ Ablation System. Both the subject device and predicate devices are based on the same endoscopic instrumentation for accessing targeted sites and visualization.
The subject device has the same Indications for Use as the predicate devices.
The subject device and predicate devices are based on the following equivalent technological elements:
- . Inserted through an endoscope to access the treatment site
- Application of nitrous oxide cryogen to ablate (freeze) the targeted tissue ●
- Use of direct visualization to the treatment area ●
- Use of a compliant balloon to position the treatment
- Use of a balloon to contain the cryogen (gas does not contact tissue)
- Use of the Catheter shaft to vent gas out of patient ●
- Use of diffuser to direct cryogen on targeted tissue ●
- User-controlled release of cryogen
- Software activated Controller ●
The Controller is reused after intermediate level cleaning and disinfection.
VII. PERFORMANCE DATA
Performance Data were provided for the C2 CryoBalloon Ablation System and its components in support of substantial equivalence determination. The following was performed on the subject C2 CryoBalloon Ablation System to evaluate physical reliability, safety, and effectiveness.
6
| Testing Type | Objectives | Results | |
|---|---|---|---|
| Bench Testing | The nonclinical testing assessed | ||
| functional performance of the | |||
| system. The following describes | |||
| the key aspects of the device that | |||
| were tested: | |||
| • Simulated Use | |||
| ○ Verify temperature | |||
| uniformity and depth of | |||
| penetration during cryogen | |||
| application. | |||
| ○ Verify system hold pressure | |||
| is maintained with no | |||
| leakage. | |||
| ○ Verify controller reliability | |||
| after 1-year of reuse. | |||
| • Dimensional Testing | |||
| ○ Verify balloon and Catheter | |||
| dimensions | |||
| ○ Verify Catheter able to pass | |||
| through 3.7mm or larger | |||
| accessory channel. | |||
| • Mechanical Integrity | |||
| ○ Verify rated burst pressure | |||
| of balloon is sufficiently | |||
| greater than nominal | |||
| operating pressure | |||
| ○ Tensile test all of the | |||
| Catheter bonds | |||
| ○ Verify balloon reliability | |||
| after repeated inflations | The subject C2 CryoBalloon | ||
| Ablation System passed all | |||
| functional testing and met all | |||
| product specification | |||
| requirements. | |||
| Software | Perform testing to verify | ||
| conformance to Guidance for the | |||
| Content of Premarket | |||
| Submissions for Software | |||
| Contained in Medical Devices, | |||
| Guidance for Industry and FDA | |||
| Staff, May 11, 2005. | The subject C2 CryoBalloon | ||
| Ablation System met all | |||
| software test requirements for | |||
| software with a Major Level | |||
| of Concern. | |||
| Electrical Safety | Perform testing to verify | ||
| conformance to the following | |||
| standards: | |||
| • ES 60601-1:2005/(R)2012 | |||
| And A1:2012 | |||
| • IEC 60601-1-2:2007 | |||
| • IEC 60601-1-6 Edition 3.1 | |||
| 2013 10 | The subject C2 CryoBalloon | ||
| Ablation System met the | |||
| electrical safety, | |||
| electromagnetic compatibility, | |||
| and coexistence test | |||
| requirements and is fully | |||
| compliant with all of the | |||
| listed standards | |||
| Testing Type | Objectives | Results | |
| Controller | |||
| Reprocessing | Perform testing to verify | ||
| conformance to Reprocessing | |||
| Medical Devices in Health Care | |||
| Settings: Validation Methods and | |||
| Labeling Guidance for Industry | |||
| and FDA Staff, March 17, 2015. |
Perform microbial ingress testing
to confirm contaminated (interior
and exterior) Controller does not
cross-contaminate the Catheter. | The subject C2 CryoBalloon
Controller's intermediate
level cleaning and
disinfection processes have
been validated per FDA
guidance.
The microbial ingress testing
demonstrated that a
contaminated Controller does
not cross-contaminate the
Catheter; therefore,
Intermediate Level Cleaning
and Disinfection are
appropriate reprocessing
processes for the subject
device. | |
| Biocompatibility | Perform testing to verify
conformance to the following
standards:
• Use of International Standard
ISO 10993-1, “Biological
evaluation of medical devices
- Part 1: Evaluation and
testing within a risk
management process,”
Guidance for Industry and
FDA Staff, June 16, 2016
• ISO 10993-1:2009
• ISO 10993-5:2009
• ISO 10993-10:2010 | The subject C2 CryoBalloon
Ablation System met the
cytotoxicity, irritation, and
sensitization requirements.
The subject device materials
are the same as the predicate
devices. | |
| Catheter
Sterilization | Perform testing to verify
conformance to the following
standards:
• ISO 11135:2014 | The subject C2 CryoBalloon
Catheter met the sterilization
and residuals requirements.
The subject Catheter | |
| Testing Type | Objectives | Results | |
| Packaging/Shelf
Life | Perform testing to verify
conformance to the following
standards:
• ISO 11607-1:2006 (Catheter
only)
• ASTM D4332-14
• ASTM D4169-14
• ASTM F2096-11 (Catheter
only)
• ASTM F88-15 (Catheter only)
• ASTM F1929-15 (Catheter
only) | The subject C2 CryoBalloon
Ablation System met the
packaging test requirements. | |
| | Usability | Perform testing to verify
conformance to Applying Human
Factors and Usability
Engineering to Medical Devices,
Guidance for Industry and FDA
Staff, February 3, 2016. | The subject C2 CryoBalloon
Ablation System was found to
be safe and effective for the
intended user, uses, and use
environment. Residual risks
do not require device
modification. |
7
8
VIII. CONCLUSIONS
The subject C2 CryoBalloon™ Ablation System (K163684) has the same intended use and indications for use as the predicate C2 CryoBalloon™ Ablation Systems (K161202). The preclinical bench performance data supports the indication for use and demonstrates that the subject device is as safe, effective, and performs as well as the predicate device. The subject device has the equivalent technological characteristics and performance data to support substantial equivalence in terms of safety and effectiveness.